Over 500 companies, including Bharat Petroleum (BPCL) and IRCTC, are set to announce their quarterly earnings on August 13, ...

Pfizer presents a good buying opportunity, but not because of potential earnings.

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine was viable.

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company delayed the results of COVID-19 vaccine trials to influence the 2020 election.

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among senior executives at the pharma company to “deliberately slow down&#822… ...

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the development of the ...

Pfizer has added another chapter to its long-running drug discovery collaboration with Chinese tech startup XtalPi, this time upgrading their molecular modeling work. The aim is to help “grasp ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022 ...